CLINICAL ENDOCRINOLOGY, cilt.85, sa.4, ss.556-560, 2016 (SCI-Expanded)
Objective Teriparatide, an anabolic agent used in the treatment of postmenopausal osteoporosis, can induce effects similar to primary hyperparathyroidism. Our objective was to evaluate the effects of teriparatide on endothelial functions, glucose metabolism and inflammation markers in patients diagnosed with postmenopausal osteoporosis.